A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Conditions

• Metastatic Breast Cancer
• Advanced Breast Cancer
• Metastatic Castration Resistant Prostate Cancer
• Metastatic Renal Cell Cancer
• Non-Small Cell Lung Cancer
• Thyroid Cancer
• Advanced/Metastatic Non-Small Cell Lung Cancer
• Advanced Gastric Cancer
• Gastrointestinal Stromal Tumor
• Hepatocellular Carcinoma
• Pancreatic Islet Cell Carcinoma
• Pancreatic Neuroendocrine Tumor

Interventions

• DRUG: sunitinib

Sponsor

Pfizer